Biomarkers in the management of COPD

European Respiratory Review

Volumn 18, Issue 112, 2009, Pages 96-104

  Lacoma, A ^a,b   Prat, C ^a,b   Andreo, F ^a,b   Dominguez J ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomarker; Chronic obstructive pulmonary disease; Exacerbation; Inflammation

Indexed keywords

ADRENOMEDULLIN; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; ENDOTHELIN 1; NEOPTERIN; PROCALCITONIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; LOWER RESPIRATORY TRACT INFECTION; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; REVIEW; STREPTOCOCCUS PNEUMONIAE;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 66549112560     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00000609     Document Type: Review

References (72)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773. (Pubitemid 47321908)
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
3. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360. (Pubitemid 36204553)
4. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832. (Pubitemid 44914209)
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812. (Pubitemid 38057722)
6. Weiss G, Murr C, Zoller H, et al. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2- derived cytokines in human monocytic cells. Clin Exp Immunol 1999; 116: 435-440. (Pubitemid 29258092)
7. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319-329. (Pubitemid 32989554)
8. Gibot S. Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care 2005; 9: 485-489. (Pubitemid 41498545)
9. Becker KL, Nylen ES, White JC, et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89: 1512-1525. (Pubitemid 38507896)
10. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86: 396-404. (Pubitemid 32109825)
11. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941-952.
12. Linscheid P, Seboek D, Zulewski H, et al. Autocrine/ paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005; 146: 2699-2708. (Pubitemid 40695573)
13. Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
14. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci 2004; 25: 219-224. (Pubitemid 38519913)
15. Beishuizen A, Hartemink KJ, Vermes I, et al. Circulating cardiovascular markers and mediators in acute illness: an update. Clin Chim Acta 2005; 354: 21-34. (Pubitemid 40320670)
16. van der Meer V, Neven AK, van den Broek PJ, et al. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005; 331: 26. (Pubitemid 40942537)
17. Ip M, Rainer TH, Lee N, et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis 2007; 59: 131-136. (Pubitemid 47484130)
18. Prat C, Dominguez J, Andreo F, et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006; 52: 169-177. (Pubitemid 43286182)
19. Prat C, Dominguez J, Rodrigo C, et al. Procalcitonin, Creactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J 2003; 22: 963-968.
20. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128: 2223-2229. (Pubitemid 41507563)
21. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607. (Pubitemid 38264177)
22. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93. (Pubitemid 43955248)
23. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008; 264: 166-176.
24. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96. (Pubitemid 47086829)
25. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37: 145-152. (Pubitemid 46066494)
26. Muller B, Suess E, Schuetz P, et al. Circulating levels of proatrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260: 568-576. (Pubitemid 44772377)
27. Prat C, Lacoma A, Dominguez J, et al. Midregional proatrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007; 55: 400-407. (Pubitemid 47611511)
28. Masia M, Papassotiriou J, Morgenthaler NG, et al. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007; 53: 2193-2201. (Pubitemid 350197304)
29. Schuetz P, Stolz D, Mueller B, et al. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008; 8: 22.
30. Lieberman D, Livnat S, Schlaeffer F, et al. IL-1β and IL-6 in community-acquired pneumonia: bacteremic pneumococcal pneumonia versus Mycoplasma pneumoniae pneumonia. Infection 1997; 25: 90-94. (Pubitemid 27145844)
31. Ortqvist A, Hedlund J, Wretlind B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995; 27: 457-462.
32. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548. (Pubitemid 39658462)
33. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580. (Pubitemid 38901515)
34. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-78. (Pubitemid 43069790)
35. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007; 131: 37-43. (Pubitemid 46122972)
36. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874. (Pubitemid 44564786)
37. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-534. (Pubitemid 46372101)
38. Takabatake N, Sata M, Abe S, et al. Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD. Respir Med 2005; 99: 485-492. (Pubitemid 40347833)
39. Radsak MP, Taube C, Haselmayer P, et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol 2007; 2007: 52040. (Pubitemid 350135068)
40. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-363.
41. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250-258.
42. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
43. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-1238. (Pubitemid 46895385)
44. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
45. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
46. Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr Opin Pulm Med 2008; 14: 95-100.
47. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19. (Pubitemid 46122969)
48. Lacoma A, Prat C, Domínguez J, et al. Utility of procalcitonin, neopterin, C-reactive protein and MR-proANP measurement in the management of exacerbations in chronic obstructive pulmonary disease. Eur Respir J 2008; 32: Suppl. 52, 479s.
49. Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis 2008; 8: 145.
50. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med 2006; 17: 88-91.
51. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
52. Bircan A, Gokirmak M, Kilic O, et al. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract 2008; 17: 202-208.
53. Phua J, Koay ES, Zhang D, et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 2006; 28: 695-702. (Pubitemid 46331989)
54. Hurst JR, Wedzicha JA. The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med 2007; 28: 525-536, v. (Pubitemid 47284586)
55. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 115-120.
56. de Kruif MD, Lemaire LC, Giebelen IA, et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008; 34: 518-522.
57. Perren A, Cerutti B, Lepori M, et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008; 36: 163-166.
58. Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257. (Pubitemid 44883863)
59. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest 2007; 131: 1557-1566. (Pubitemid 46762366)
60. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459-467. (Pubitemid 37000120)
61. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012. (Pubitemid 38269277)
62. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931. (Pubitemid 41598207)
63. Tzortzaki EG, Lambiri I, Vlachaki E, et al. Biomarkers in COPD. Curr Med Chem 2007; 14: 1037-1048. (Pubitemid 46672638)
64. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007; 62: 595-601. (Pubitemid 47056886)
65. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133: 1088-1094.
66. Stolz D, Christ-CrainM,Morgenthaler NG, et al. Plasma proadrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134: 263-272.
67. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255. (Pubitemid 46203128)
68. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907. (Pubitemid 44911101)
69. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853. (Pubitemid 44570304)
70. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133: 1336-1343.
71. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 2006; 61: 23-28. (Pubitemid 43106973)
72. Price CP, Kricka LJ. Improving healthcare accessibility through point-of-care technologies. Clin Chem 2007; 53: 1665-1675. (Pubitemid 47340064)